Jonathan Hopper
Chief Tech/Sci/R&D Officer at VERICEL CORPORATION
Net worth: 3 M $ as of 2024-03-30
Profile
Jonathan Mark Hopper is currently the Chief Medical Officer at Vericel Corp.
He previously worked as the Vice President-Global Medical Director at Stryker Corp from 2010 to 2014, the Chief Medical Officer at Osiris Therapeutics, Inc. from 2014 to 2016, and the Medical Director at Ferring Pharmaceuticals, Inc. in 2017-2018.
He also served as the Senior Medical Officer at the United Kingdom Department of Health & Social Care and as the Vice President-Medical Affairs at ConvaTec, Inc. from 2006 to 2010.
Dr. Hopper holds an MBA from Keele University and an undergraduate degree from the University of Birmingham Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VERICEL CORPORATION
0.12% | 2024-03-07 | 58,110 ( 0.12% ) | 3 M $ | 2024-03-30 |
Jonathan Hopper active positions
| Companies | Position | Start |
|---|---|---|
| VERICEL CORPORATION | Chief Tech/Sci/R&D Officer | 2018-08-19 |
Former positions of Jonathan Hopper
| Companies | Position | End |
|---|---|---|
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Chief Tech/Sci/R&D Officer | 2018-07-31 |
| OSIRIS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2016-04-11 |
| STRYKER CORPORATION | Chief Tech/Sci/R&D Officer | 2014-10-31 |
ConvaTec, Inc.
 ConvaTec, Inc. Medical SpecialtiesHealth Technology ConvaTec, Inc. engages in the manufacture of medical products and technologies focused on therapies for the management of chronic conditions. It specializes in the wound care, ostomy care, continence and critical care, and infusion devices. The company was founded in 1978 and is headquartered in Bridgewater, NJ. | Chief Tech/Sci/R&D Officer | 2010-07-31 |
| United Kingdom Department of Health & Social Care | Corporate Officer/Principal | - |
Training of Jonathan Hopper
| Keele University | Masters Business Admin |
| University of Birmingham Medical School | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| STRYKER CORPORATION | Health Technology |
| VERICEL CORPORATION | Health Technology |
| Private companies | 4 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
| United Kingdom Department of Health & Social Care | Government |
ConvaTec, Inc.
ConvaTec, Inc. Medical SpecialtiesHealth Technology ConvaTec, Inc. engages in the manufacture of medical products and technologies focused on therapies for the management of chronic conditions. It specializes in the wound care, ostomy care, continence and critical care, and infusion devices. The company was founded in 1978 and is headquartered in Bridgewater, NJ. | Health Technology |
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
- Stock Market
- Insiders
- Jonathan Hopper
